Marquette Asset Management LLC purchased a new stake in Rafael Holdings, Inc. (NYSE:RFL – Get Rating) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 49,256 shares of the company’s stock, valued at approximately $92,000. Marquette Asset Management LLC owned approximately 0.24% of Rafael as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. Private Advisor Group LLC acquired a new stake in Rafael during the 2nd quarter valued at approximately $25,000. UBS Group AG boosted its stake in Rafael by 143.7% during the 1st quarter. UBS Group AG now owns 13,648 shares of the company’s stock worth $35,000 after purchasing an additional 8,047 shares during the last quarter. Fisher Asset Management LLC acquired a new position in shares of Rafael during the 1st quarter valued at about $55,000. Atria Wealth Solutions Inc. acquired a new position in shares of Rafael during the 1st quarter valued at about $81,000. Finally, PDT Partners LLC acquired a new position in shares of Rafael during the 4th quarter valued at about $117,000. 43.19% of the stock is currently owned by institutional investors.
Rafael Trading Down 3.5 %
NYSE RFL traded down $0.07 during trading hours on Friday, reaching $1.95. The company had a trading volume of 64,874 shares, compared to its average volume of 154,483. The stock has a 50-day moving average of $2.18 and a 200 day moving average of $2.14. Rafael Holdings, Inc. has a 1-year low of $1.60 and a 1-year high of $37.50. The stock has a market capitalization of $40.57 million, a P/E ratio of -0.26 and a beta of 1.79.
Insiders Place Their Bets
Rafael Holdings, Inc holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.
- Get a free copy of the StockNews.com research report on Rafael (RFL)
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 2 Semiconductor Stocks To Watch For Reversals
Receive News & Ratings for Rafael Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rafael and related companies with MarketBeat.com's FREE daily email newsletter.